A study of "Tocilizumab treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants". Chauvin et al

Supplementary Dataset for the manuscript "Tocilizumab treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants". Description of each patient according to disease severity and treatment. 55 out of 69 patients were recruited during the first COVID-19 wave while 14 patients were recruited during the second/third wave of COVID-19.